Table 2.
Variable |
|
All patients1 |
IHC-TMA1 |
IF-TMA1 |
---|---|---|---|---|
n (%) | n (%) | n (%) | ||
Total |
|
33 (100) |
16 (48) |
17 (52) |
Gender |
Female |
13 (39) |
7 (43) |
6 (35) |
Male |
20 (61) |
9 (57) |
11 (65) |
|
Age (mean) |
|
59.03 |
61.7 |
56 |
pT stage |
T1 |
0 (0) |
0 (0) |
0 (0) |
T2 |
16 (48) |
7 (43) |
9 (53) |
|
T3 |
15 (45) |
9 (57) |
6 (35) |
|
T4 |
2 (6) |
0 (0) |
2 (12) |
|
Lymph node |
N0 |
12 (36) |
4 (25) |
8 (47) |
N1 |
3 (9) |
3 (18) |
0 (0) |
|
Nx |
18 (55) |
9 (56) |
9 (53) |
|
Metastasis |
M0 |
23 (69) |
11 (69) |
12 (70) |
M1 |
8 (24) |
4 (25) |
4 (24) |
|
Mx |
2 (7) |
1 (6) |
1 (6) |
|
Tumor grade |
G1 |
4 (12) |
4 (25) |
0 (0) |
G2 |
25 (76) |
10 (62) |
15 (88) |
|
G3 |
3 (9) |
1 (6) |
2 (12) |
|
G4 |
0 (0) |
0 (0) |
0 (0) |
|
Unknown | 1 (3) | 1 (6) | 0 (0) |
1subgroup with clear cell histology; IHC, immunohistochemical analysis; IF, immunofluorescence analysis; TMA, tissue microarray analysis.